bluebird bio, Inc. (NASDAQ:BLUE) Short Interest Up 13.6% in November

bluebird bio, Inc. (NASDAQ:BLUE) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 49,570,000 shares, a growth of 13.6% from the November 15th total of 43,640,000 shares. Based on an average daily volume of 7,620,000 shares, the short-interest ratio is presently 6.5 days.

Analyst Ratings Changes

BLUE has been the topic of a number of research reports. Wells Fargo & Company decreased their price target on bluebird bio from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. Barclays cut their price objective on bluebird bio from $80.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. JPMorgan Chase & Co. lowered bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Finally, StockNews.com initiated coverage on bluebird bio in a research report on Thursday. They set a “sell” rating on the stock. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, bluebird bio presently has an average rating of “Hold” and a consensus price target of $49.14.

Hedge Funds Weigh In On bluebird bio

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of bluebird bio by 3.7% during the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after purchasing an additional 166,771 shares during the last quarter. State Street Corp grew its holdings in shares of bluebird bio by 1.1% during the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after purchasing an additional 43,382 shares during the last quarter. FMR LLC grew its holdings in shares of bluebird bio by 8.1% during the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after purchasing an additional 186,903 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after purchasing an additional 1,013,144 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of bluebird bio by 19.4% during the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company’s stock worth $675,000 after purchasing an additional 111,574 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Stock Down 3.8 %

NASDAQ:BLUE traded down $0.24 during trading hours on Monday, hitting $6.10. The company’s stock had a trading volume of 58,453 shares, compared to its average volume of 386,852. The stock has a market capitalization of $1.19 billion, a P/E ratio of -3.39 and a beta of 0.72. The stock has a fifty day moving average of $8.68 and a 200-day moving average of $13.96. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. bluebird bio has a 52-week low of $5.80 and a 52-week high of $64.00.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($7.20) earnings per share (EPS) for the quarter. The firm had revenue of $18.57 million for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. On average, equities analysts forecast that bluebird bio will post -1.35 earnings per share for the current year.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.